Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders

E-ISSN： 1875-5607|9|12|1429-1438

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.9, Iss.12, 2009-10, pp. : 1429-1438

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relevance of Dopamine D2/Neurotensin NTS1 and NMDA/Neurotensin NTS1 Receptor Interaction in Psychiatric and Neurodegenerative Disorders

Current Medicinal Chemistry, Vol. 19, Iss. 3, 2012-01 ,pp. : 304-316

Bentham Science Publishers

Access to resources Recommend Favorite

Novel EP1 receptor antagonists

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 3, 2004-03 ,pp. : 435-438

Informa Healthcare

Access to resources Recommend Favorite

Novel chemokine CCR1 receptor antagonists

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 8, 2001-08 ,pp. : 1355-1357

Informa Healthcare

Access to resources Recommend Favorite

Galanin Receptor Antagonists: A Potential Novel Pharmacological Treatment for Mood Disorders

By Ögren Sven Ove Kuteeva Eugenia Hökfelt Tomas Kehr Jan

CNS Drugs, Vol. 20, Iss. 8, 2006-01 ,pp. : 633-654

Adis International

Access to resources Recommend Favorite

Adenosine type 1 receptor antagonists in fluid retaining disorders

By Welch William J

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1553-1562

Informa Healthcare

Access to resources Recommend Favorite